Skip to main content
Contact Us
Subscribe
E-Edition
72°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Allovir Inc
(NQ:
ALVR
)
0.9534
+0.0234 (+2.52%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allovir Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Mid-Day Market Update: Nasdaq Down Over 150 Points; Netflix Shares Drop Following Earnings Report
April 20, 2022
U.S. stocks traded mixed midway through trading, with the Nasdaq composite dropping more than 150 points on Wednesday.
Via
Benzinga
28 Stocks Moving In Wednesday's Mid-Day Session
April 20, 2022
Gainers Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) climbed 58.3% to $2.2950 after jumping around 22% on Tuesday. AlloVir, Inc. (NASDAQ: ALVR) shares climbed 39% to $7.52...
Via
Benzinga
Why Is AlloVir (ALVR) Stock Up 30% Today?
April 20, 2022
AlloVir (ALVR) stock is taking off on Wednesday following an update from the U.S. Food and Drug Administration (FDA) on posoleucel.
Via
InvestorPlace
Mid-Morning Market Update: Markets Mixed; Dow Jumps 250 Points
April 20, 2022
U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 250 points on Wednesday.
Via
Benzinga
Recap: AlloVir Q4 Earnings
February 10, 2022
AlloVir (NASDAQ:ALVR) reported its Q4 earnings results on Thursday, February 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Analyst Ratings For AlloVir
February 01, 2022
Over the past 3 months, 4 analysts have published their opinion on AlloVir (NASDAQ:ALVR) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
Why AlloVir Stock Is Surging Today
April 20, 2022
AlloVir Inc (NASDAQ: ALVR) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Regenerative Medicine...
Via
Benzinga
The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study
April 20, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
April 20, 2022
Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 40.0% to $1.4 during Wednesday's pre-market session. The company's market cap stands at $39.8 million....
Via
Benzinga
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients
April 20, 2022
From
AlloVir
Via
Business Wire
Stocks That Hit 52-Week Lows On Monday
April 04, 2022
On Monday, 78 companies set new 52-week lows. Key Facts About Today's 52-Week Lows: Citigroup (NYSE:C) was the biggest company by market cap to set a new 52-week low....
Via
Benzinga
AlloVir Appoints Shawn Tomasello to Its Board of Directors
March 31, 2022
From
AlloVir
Via
Business Wire
Stocks That Hit 52-Week Lows On Thursday
March 31, 2022
On Thursday, 92 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...
Via
Benzinga
AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients
March 22, 2022
From
AlloVir
Via
Business Wire
AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 11, 2022
From
AlloVir
Via
Business Wire
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook
February 10, 2022
From
AlloVir
Via
Business Wire
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation
January 05, 2022
From
AlloVir
Via
Business Wire
AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022
From
AlloVir
Via
Business Wire
Stocks Hitting New 52-Week Lows Today
January 03, 2022
On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was...
Via
Benzinga
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
December 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral...
Via
Benzinga
AlloVir Announces Departure of Chief Medical Officer Augustin Melian
December 16, 2021
From
AlloVir
Via
Business Wire
AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting
December 11, 2021
From
AlloVir
Via
Business Wire
AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 15, 2021
From
AlloVir, Inc.
Via
Business Wire
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
AlloVir Reports Third Quarter 2021 Financial Results
November 05, 2021
From
AlloVir
Via
Business Wire
52 Biggest Movers From Yesterday
October 20, 2021
Gainers Xiaobai Maimai Inc. (NASDAQ: HX) shares climbed 42.6% to close at $9.51 on Tuesday. Xiaobai Maimai said Xiaobao An resigned as CEO. Kaival Brands Innovations Group...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 19, 2021
Gainers Redhill Biopharma (NASDAQ:RDHL) stock increased by 18.27% to $5.76 during Tuesday's regular session. Redhill Biopharma's stock is trading at a volume of 2....
Via
Benzinga
44 Biggest Movers From Yesterday
October 05, 2021
Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of...
Via
Benzinga
FDA Grants Orphan Drug Designation (ODD) to AlloVir’s Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis
October 04, 2021
From
AlloVir, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.